PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
20524801-12	2010	These administration-time-dependent effects of spirapril seem to be a class-related feature, and may be associated with the nocturnal activation of the renin-angiotensin-aldosterone system.	spirapril	47-56	renin	Homo sapiens	152-157
16710253-0	2006	[Advantages of long-term controlled stepwise therapy of arterial hypertension with the use of angiotensin converting enzyme inhibitor spirapril].	spirapril	134-143	angiotensin I converting enzyme	Homo sapiens	94-123
18713951-10	2008	Statistically significant, but very low currents were only observed for lisinopril, enalapril, quinapril, and benazepril at PEPT1 and for spirapril at PEPT2.	spirapril	138-147	solute carrier family 15 member 2	Homo sapiens	151-156
16474309-6	2006	Moexipril and spirapril caused lowering of elevated levels of leptin.	spirapril	14-23	leptin	Homo sapiens	62-68
16126915-4	2005	Second, Spirapril, an inhibitor of the angiotensin-converting enzyme (ACE), which passes the blood-brain barrier, did not influence the alcohol consumption in the TGR(ASrAOGEN)680, but it significantly reduced alcohol intake in wild-type rats.	spirapril	8-17	angiotensin I converting enzyme	Rattus norvegicus	39-68
16126915-4	2005	Second, Spirapril, an inhibitor of the angiotensin-converting enzyme (ACE), which passes the blood-brain barrier, did not influence the alcohol consumption in the TGR(ASrAOGEN)680, but it significantly reduced alcohol intake in wild-type rats.	spirapril	8-17	angiotensin I converting enzyme	Rattus norvegicus	70-73
10499560-1	1999	Spirapril is a new angiotensin-converting enzyme (ACE) inhibitor.	spirapril	0-9	angiotensin I converting enzyme	Homo sapiens	19-48
12494232-0	2002	[Effect of angiotensin converting enzyme inhibitor spirapril on dimensions of experimental myocardial infarction, development of ischemic tachyarrhythmias, and ischemic adaptation of the heart].	spirapril	51-60	angiotensin I converting enzyme	Homo sapiens	11-40
11325479-8	2001	Cyclization reactions of crystalline and amorphous angiotensin-converting enzyme (ACE) inhibitors (spirapril hydrochloride, quinapril hydrochloride, and moexipril) are presented which investigate mobility and chemical reactivity.	spirapril	99-122	angiotensin I converting enzyme	Homo sapiens	51-80
11325479-8	2001	Cyclization reactions of crystalline and amorphous angiotensin-converting enzyme (ACE) inhibitors (spirapril hydrochloride, quinapril hydrochloride, and moexipril) are presented which investigate mobility and chemical reactivity.	spirapril	99-122	angiotensin I converting enzyme	Homo sapiens	82-85
12613273-0	2002	[Influence of ACE inhibitor spirapril on left ventricular hypertrophy].	spirapril	28-37	angiotensin I converting enzyme	Homo sapiens	14-17
12200795-3	2002	METHODS: Twenty-three proteinuric patients were administered the ACE inhibitor spirapril at a starting dose of 3 to 6 mg/d.	spirapril	79-88	angiotensin I converting enzyme	Homo sapiens	65-68
11929321-3	2002	The pharmacokinetic properties of five newer ACE inhibitors (trandolapril, moexipril, spirapril, temocapril and imidapril) are reviewed in this update.	spirapril	86-95	angiotensin I converting enzyme	Homo sapiens	45-48
11773991-0	2001	ACE-inhibitor therapy with spirapril increases nocturnal hypotensive episodes in elderly hypertensive patients.	spirapril	27-36	angiotensin I converting enzyme	Homo sapiens	0-3
11773991-9	2001	In conclusion, ACE-inhibitor therapy with spirapril significantly increased hypotensive episodes in elderly hypertensive patients which may worsen their cerebral and myocardial circulation.	spirapril	42-51	angiotensin I converting enzyme	Homo sapiens	15-18
11220886-0	2000	[The ACE inhibitor spirapril in chronic renal failure, hypertension and diabetic nephropathy].	spirapril	19-28	angiotensin I converting enzyme	Homo sapiens	5-8
10499560-1	1999	Spirapril is a new angiotensin-converting enzyme (ACE) inhibitor.	spirapril	0-9	angiotensin I converting enzyme	Homo sapiens	50-53
10499560-12	1999	Possible advantages of spirapril compared to other ACE inhibitors are the dual mechanism of elimination, the lack of need for dose titration and a low incidence of cough.	spirapril	23-32	angiotensin I converting enzyme	Homo sapiens	51-54
10499562-0	1999	ACE inhibition in chronic renal failure and in the treatment of diabetic nephropathy: focus on spirapril.	spirapril	95-104	angiotensin I converting enzyme	Homo sapiens	0-3
9208336-8	1997	There was also a tendency in the 2-hour insulin levels to increase in both the spirapril and the atenolol treatment group after the 12-month treatment period.	spirapril	79-88	insulin	Homo sapiens	40-47
10100366-4	1999	ACE activity, which was depressed by the previous spirapril treatment, decreased further (from 9.5 +/- 3.1 to 1.4 +/- 1.0 nmol/ml/min), (p < 0.05).	spirapril	50-59	angiotensin I converting enzyme	Homo sapiens	0-3
9300315-8	1997	Spirapril alone reduced blood pressure and increased PRA and when given before 2HE-NECA potentiated its depressor and renin-stimulating effects by 44% and 69%, respectively.	spirapril	0-9	renin	Rattus norvegicus	118-123
10379634-2	1999	METHODS: The beta-receptor blocking agent atenolol (50 mg), the calcium antagonist isradipine SRO (2.5 mg), the diuretic hydrochlorothiazide (25 mg) and the ACE inhibitor spirapril (6 mg) once daily were given in a double-blind crossover schedule for 8 weeks.	spirapril	171-180	angiotensin I converting enzyme	Homo sapiens	157-160
9657622-4	1998	The effects of treatment on pressor hormone profiles differed among groups, as spirapril tended to suppress angiotensin II and norepinephrine, whereas isradipine had opposite effects.	spirapril	79-88	angiotensinogen	Homo sapiens	108-122
9330124-1	1997	BACKGROUND: This study was done to determine whether the difference in duration of action of the long-acting angiotensin-converting enzyme (ACE) inhibitor spirapril compared with the short-acting ACE inhibitor captopril affects clinical efficacy in patients with congestive heart failure.	spirapril	155-164	angiotensin I converting enzyme	Homo sapiens	109-138
9330124-1	1997	BACKGROUND: This study was done to determine whether the difference in duration of action of the long-acting angiotensin-converting enzyme (ACE) inhibitor spirapril compared with the short-acting ACE inhibitor captopril affects clinical efficacy in patients with congestive heart failure.	spirapril	155-164	angiotensin I converting enzyme	Homo sapiens	140-143
9330124-7	1997	Serum ACE activity was significantly different between the two treatment groups during treatment (P < .0001) and showed only a significant decrease in the spirapril group.	spirapril	158-167	angiotensin I converting enzyme	Homo sapiens	6-9
9330124-9	1997	CONCLUSIONS: This study showed that the effects of the ACE inhibitors spirapril and captopril on exercise capacity are not related to the degree of inhibition of serum ACE activity.	spirapril	70-79	angiotensin I converting enzyme	Homo sapiens	55-58
8638865-0	1996	ACE inhibition with spirapril improves diastolic function at rest independent of vasodilation during treatment with spirapril in mild to moderate hypertension.	spirapril	20-29	angiotensin I converting enzyme	Homo sapiens	0-3
8873580-7	1996	This exercise-induced increase in PF4 was significantly reduced by spirapril as compared with placebo (P < 0.05).	spirapril	67-76	platelet factor 4	Homo sapiens	34-37
9601863-2	1997	Spirapril, an ACE-inhibitor without the SH group was tested in a randomized double-blind multicentric study in patients with chronic symptomatic heart failure (NYHA II-IV).	spirapril	0-9	angiotensin I converting enzyme	Homo sapiens	14-17
9601864-2	1997	The CASSIS study was a double-blind multicentric controlled Czech and Slovak study focused on treatment of chronic heart failure with the ACE inhibitor spirapril; it was conducted for 12 weeks.	spirapril	152-161	angiotensin I converting enzyme	Homo sapiens	138-141
9601864-9	1997	Spirapril proved to be a well tolerated ACE-inhibitor.	spirapril	0-9	angiotensin I converting enzyme	Homo sapiens	40-43
9601864-15	1997	The results of the second year of erxtension indicate that spirapril is a very effective and safe ACE-inhibitor which will extend in a significant way therapeutic means in patients with chronic heart failure.	spirapril	59-68	angiotensin I converting enzyme	Homo sapiens	98-101
9056690-7	1997	However, after a single oral dose of a combination of the angiotensin converting enzyme inhibitor spirapril and the calcium entry blocker isradipine, the increase in arterial compliance in response to the maximum dose of intraarterial acetylcholine was enhanced in normotensives (0.38 +/- 1.23 to 0.76 +/- 1.01 mm2/mm Hg x 10(-3), P < .05), but not in hypertensives (+0.41 +/- 1.26 to 0.36 +/- 1.31 mm2/mm Hg x 10(-3), not significant), and differed significantly between normotensive and hypertensive subjects (P < .05).	spirapril	98-107	angiotensin I converting enzyme	Homo sapiens	58-87
8737752-0	1996	Efficacy and safety of spirapril, a new ace-inhibitor, in elderly hypertensive patients.	spirapril	23-32	angiotensin I converting enzyme	Homo sapiens	40-43
8824693-0	1996	Effects of acute and chronic angiotensin converting enzyme inhibition by spirapril on cardiovascular regulation in essential hypertensive patients.	spirapril	73-82	angiotensin I converting enzyme	Homo sapiens	29-58
8824693-3	1996	The effects of a first dose and of chronic treatment with spirapril, a novel angiotensin converting enzyme (ACE) inhibitor, on short-term blood pressure and heart rate fluctuations were assessed by fast Fourier spectral analysis.	spirapril	58-67	angiotensin I converting enzyme	Homo sapiens	77-106
8824693-3	1996	The effects of a first dose and of chronic treatment with spirapril, a novel angiotensin converting enzyme (ACE) inhibitor, on short-term blood pressure and heart rate fluctuations were assessed by fast Fourier spectral analysis.	spirapril	58-67	angiotensin I converting enzyme	Homo sapiens	108-111
8737955-6	1996	Spirapril significantly inhibited plasma converting enzyme activity (-96% at 4 h), increased plasma renin activity (+505% at 4 h), and decreased plasma aldosterone (-46% at 24 h), norepinephrine (-31% at 24 h) and atrial natriuretic factor (-33% at 7 h).	spirapril	0-9	renin	Homo sapiens	100-105
8737752-1	1996	OBJECTIVE: To compare the safety, efficacy, tolerability and duration of the antihypertensive effect of an ACE-inhibitor spirapril 3 mg or 6 mg in elderly (> or = 60 y) hypertensive patients in a multicentre, observational, double-blind randomised study.	spirapril	121-130	angiotensin I converting enzyme	Homo sapiens	107-110
8937511-5	1996	The brain ACE activity was determined ex vivo immediately after the hot-plate test, and showed to be suppressed for the groups repeatedly treated with spirapril or trandolapril.	spirapril	151-160	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Mus musculus	10-13
7968874-0	1994	[Kidney function in hypertensive patients with chronic renal failure treated with the dual eliminated ACE-inhibitor spirapril].	spirapril	116-125	angiotensin I converting enzyme	Homo sapiens	102-105
8553592-15	1995	The results of the study indicate that spirapril is an effective and well tolerated ACE inhibitor in the treatment of hypertension and its combination with bopindolol is equally suitable as the combination of spirapril with hydrochlorothiazide.	spirapril	39-48	angiotensin I converting enzyme	Homo sapiens	84-87
7601014-2	1995	Spirapril is a non-sulfhydryl angiotensin converting enzyme (ACE) inhibitor prodrug which is converted to the active metabolite spiraprilat following oral administration, and which has been evaluated primarily for the treatment of hypertension.	spirapril	0-9	angiotensin I converting enzyme	Homo sapiens	61-64
7723338-1	1995	Spirapril is a new angiotensin-converting enzyme (ACE) inhibitor with a long duration of action.	spirapril	0-9	angiotensin I converting enzyme	Homo sapiens	19-48
7723338-1	1995	Spirapril is a new angiotensin-converting enzyme (ACE) inhibitor with a long duration of action.	spirapril	0-9	angiotensin I converting enzyme	Homo sapiens	50-53
7723338-5	1995	Serum ACE activity after 1, 6, and 12 weeks was significantly reduced in patients receiving spirapril, but not in those receiving captopril.	spirapril	92-101	angiotensin I converting enzyme	Homo sapiens	6-9
7723338-13	1995	Despite a significantly prolonged decrease in MAP and serum ACE activity in spirapril-treated patients, no marked differences in RBF were noted between the two ACE inhibitors.	spirapril	76-85	angiotensin I converting enzyme	Homo sapiens	60-63
7968874-1	1994	PATIENTS AND METHOD: Spirapril is a recent ACE inhibitor with a both renal and hepatic elimination pathway.	spirapril	21-30	angiotensin I converting enzyme	Homo sapiens	43-46
8205299-2	1994	The acute effects of the ACE inhibitor spirapril on renal function were investigated in 10 patients with mild-to-moderate renal failure (serum creatinine of 1.5-2.5 mg/dl).	spirapril	39-48	angiotensin I converting enzyme	Homo sapiens	25-28
8061843-6	1994	If there is concern over drug accumulation in patients with impaired renal function, those ACE inhibitors (such as spirapril) with dual routes of elimination would then appear to be the agents of choice.	spirapril	115-124	angiotensin I converting enzyme	Homo sapiens	91-94
8061851-0	1994	Angiotensin-converting enzyme inhibition with spirapril in patients with coronary artery disease.	spirapril	46-55	angiotensin I converting enzyme	Homo sapiens	0-29
11835060-0	1994	The Interaction of Hydrochlorothiazide with Spirapril: A Novel Ace Inhibitor.	spirapril	44-53	angiotensin I converting enzyme	Homo sapiens	63-66
11835060-1	1994	In an open-label, randomized trial using a 3 x 3 Latin square design, single doses of 24 mg of the ACE inhibitor spirapril, or 50 mg hydrochlorothiazide, or their combination were given to 18 healthy male volunteers.	spirapril	113-122	angiotensin I converting enzyme	Homo sapiens	99-102
7521451-9	1994	In contrast, spirapril decreased BP; this effect was associated with significant increments in renin and decrements in ALDO and ANF, without changes in plasma and urinary cyclic GMP.	spirapril	13-22	renin	Rattus norvegicus	95-100
7521451-9	1994	In contrast, spirapril decreased BP; this effect was associated with significant increments in renin and decrements in ALDO and ANF, without changes in plasma and urinary cyclic GMP.	spirapril	13-22	natriuretic peptide A	Rattus norvegicus	128-131
8061851-1	1994	In a randomized double-blind, placebo-controlled, crossover trial, the potential anti-ischaemic action of the angiotensin-converting enzyme (ACE) inhibitor spirapril was studied in 19 patients with coronary artery disease (CAD) and reproducible exercise-induced ST-segment depression, but without hypertension or congestive heart failure.	spirapril	156-165	angiotensin I converting enzyme	Homo sapiens	110-139
8112517-2	1993	We examined the effect of spirapril, a potent angiotensin converting enzyme (ACE) inhibitor, on the number of capsaicin-induced coughs in rats and compared with that of enalapril.	spirapril	26-35	angiotensin I converting enzyme	Rattus norvegicus	46-75
8061851-1	1994	In a randomized double-blind, placebo-controlled, crossover trial, the potential anti-ischaemic action of the angiotensin-converting enzyme (ACE) inhibitor spirapril was studied in 19 patients with coronary artery disease (CAD) and reproducible exercise-induced ST-segment depression, but without hypertension or congestive heart failure.	spirapril	156-165	angiotensin I converting enzyme	Homo sapiens	141-144
8112517-2	1993	We examined the effect of spirapril, a potent angiotensin converting enzyme (ACE) inhibitor, on the number of capsaicin-induced coughs in rats and compared with that of enalapril.	spirapril	26-35	angiotensin I converting enzyme	Rattus norvegicus	77-80
8112517-11	1993	These results suggest that cough induced activity, one of the most serious side effects associated with chronic treatment with ACE inhibitors, of spirapril is relatively lower than that of enalapril.	spirapril	146-155	angiotensin I converting enzyme	Rattus norvegicus	127-130
8221761-12	1993	CONCLUSIONS: Chronic converting enzyme inhibition by spirapril prevents the isobaric aortic diameter reduction induced by renovascular hypertension in conscious dogs and decreases aortic stiffness, in particular by changing the elastic behaviour of the elastin fibres rather than of the collagen fibres.	spirapril	53-62	elastin	Canis lupus familiaris	253-260
8473550-1	1993	Sixteen essential hypertensive patients were entered into a protocol assessing the effect of Spirapril, an angiotensin-converting enzyme (ACE) inhibitor, on blood pressure, the renin-aldosterone system, and renal function.	spirapril	93-102	angiotensin I converting enzyme	Homo sapiens	107-136
7687720-5	1993	Three weeks later, treatment with the angiotensin-converting enzyme (ACE) inhibitor spirapril (10 mg/kg in food) or placebo was started.	spirapril	84-93	angiotensin I converting enzyme	Rattus norvegicus	38-67
7687720-5	1993	Three weeks later, treatment with the angiotensin-converting enzyme (ACE) inhibitor spirapril (10 mg/kg in food) or placebo was started.	spirapril	84-93	angiotensin I converting enzyme	Rattus norvegicus	69-72
8473550-1	1993	Sixteen essential hypertensive patients were entered into a protocol assessing the effect of Spirapril, an angiotensin-converting enzyme (ACE) inhibitor, on blood pressure, the renin-aldosterone system, and renal function.	spirapril	93-102	angiotensin I converting enzyme	Homo sapiens	138-141
8473550-4	1993	Spirapril stimulated plasma renin activity and suppressed ACE throughout the entire protocol.	spirapril	0-9	renin	Homo sapiens	28-33
8473550-4	1993	Spirapril stimulated plasma renin activity and suppressed ACE throughout the entire protocol.	spirapril	0-9	angiotensin I converting enzyme	Homo sapiens	58-61
8473550-8	1993	The authors conclude that the ACE inhibitor, Spirapril, when used as an effective antihypertensive agent, preserves renal function, lowers renal vascular resistance, and decreases urinary albumin excretion.	spirapril	45-54	angiotensin I converting enzyme	Homo sapiens	30-33
1325513-2	1992	DESIGN: A single-blind placebo-controlled study in two parallel groups of eight hypertensive subjects receiving a once-daily dose of the ACE inhibitor, spirapril, of either 12.5 or 25 mg.	spirapril	152-161	angiotensin I converting enzyme	Homo sapiens	137-140
8466734-2	1993	The angiotensin-converting enzyme (ACE) inhibitor spirapril, at a dose of 6 mg/day, was added to the treatment of those not responding to 5 mg/day isradipine SRO alone.	spirapril	50-59	angiotensin I converting enzyme	Homo sapiens	4-33
8466734-2	1993	The angiotensin-converting enzyme (ACE) inhibitor spirapril, at a dose of 6 mg/day, was added to the treatment of those not responding to 5 mg/day isradipine SRO alone.	spirapril	50-59	angiotensin I converting enzyme	Homo sapiens	35-38
8381736-6	1993	Plasma renin activity in the spirapril-treated group was significantly elevated compared with that in the vehicle group at any time (P < 0.01).	spirapril	29-38	renin	Rattus norvegicus	7-12
8381736-8	1993	The ratio of renal renin mRNA to beta-actin mRNA in the spirapril-treated group was higher than that in the control group (P < 0.01).	spirapril	56-65	renin	Rattus norvegicus	19-24
8381736-8	1993	The ratio of renal renin mRNA to beta-actin mRNA in the spirapril-treated group was higher than that in the control group (P < 0.01).	spirapril	56-65	actin, beta	Rattus norvegicus	33-43
8381736-10	1993	At 28 days, plasma renin activity in the spirapril-treated group was significantly elevated compared with that at 14 days (P < 0.05).	spirapril	41-50	renin	Rattus norvegicus	19-24
8276049-0	1993	Pharmacokinetics and haemodynamic effects of a single oral dose of the novel ACE inhibitor spirapril in patients with chronic liver disease.	spirapril	91-100	angiotensin I converting enzyme	Homo sapiens	77-80
8276049-1	1993	The pharmacokinetics and haemodynamic effects of orally administered spirapril, a novel angiotensin-converting enzyme (ACE) inhibitor, have been investigated in patients with liver cirrhosis (n = 10), in patients with chronic, non-cirrhotic liver disease (n = 8) and in a control group of healthy subjects (n = 16).	spirapril	69-78	angiotensin I converting enzyme	Homo sapiens	88-117
1325513-6	1992	RESULTS: Both for the lower and higher doses of spirapril, the time-course of changes of spiraprilat, the active metabolite of spirapril, and ACE activity was similar but the maximal rise in angiotensin I was twofold higher after 2 weeks administration than after the first dose.	spirapril	48-57	angiotensinogen	Homo sapiens	191-204
1325513-7	1992	Angiotensin II after the first dose of spirapril fell rapidly, with lowest values 2 to 4 h after dosing.	spirapril	39-48	angiotensinogen	Homo sapiens	0-14
1325513-9	1992	Compared with these first-dose responses the initial maximal degree of angiotensin II suppression after 2 weeks administration of either dose was similar, but during the subsequent hours the degree of angiotensin II suppression tended to be less with the lower and was significantly less with the higher dose of spirapril.	spirapril	312-321	angiotensinogen	Homo sapiens	201-215
1325513-12	1992	CONCLUSIONS: Repeated ACE inhibitor treatment with once-daily spirapril leads to a partial escape of ACE inhibition, as reflected by a shorter duration of angiotensin II suppression.	spirapril	62-71	angiotensin I converting enzyme	Homo sapiens	22-25
1325513-12	1992	CONCLUSIONS: Repeated ACE inhibitor treatment with once-daily spirapril leads to a partial escape of ACE inhibition, as reflected by a shorter duration of angiotensin II suppression.	spirapril	62-71	angiotensin I converting enzyme	Homo sapiens	101-104
1325513-12	1992	CONCLUSIONS: Repeated ACE inhibitor treatment with once-daily spirapril leads to a partial escape of ACE inhibition, as reflected by a shorter duration of angiotensin II suppression.	spirapril	62-71	angiotensinogen	Homo sapiens	155-169
1813122-1	1991	STUDY OBJECTIVE: The aim was to compare the effects of two novel angiotensin converting enzyme (ACE) inhibitors, spirapril and zofenopril, on cardiac remodelling in rats with congestive heart failure after myocardial infarction.	spirapril	113-122	angiotensin I converting enzyme	Rattus norvegicus	65-94
1813122-1	1991	STUDY OBJECTIVE: The aim was to compare the effects of two novel angiotensin converting enzyme (ACE) inhibitors, spirapril and zofenopril, on cardiac remodelling in rats with congestive heart failure after myocardial infarction.	spirapril	113-122	angiotensin I converting enzyme	Rattus norvegicus	96-99
1659958-4	1991	In SHR, at the established hypertensive stage, the prolonged antihypertensive effect induced by a single oral dose of spirapril was closely correlated to the long-lasting inhibition of ACE in aortae and mesenteric arteries.	spirapril	118-127	angiotensin I converting enzyme	Rattus norvegicus	185-188
1724540-1	1991	The acute hemodynamic, hormonal, and pharmacokinetic responses to the oral angiotensin-converting enzyme (ACE) inhibitor spirapril were studied in 15 patients with moderate to severe congestive heart failure in a baseline controlled dose-ranging study.	spirapril	121-130	angiotensin I converting enzyme	Homo sapiens	75-104
1724540-1	1991	The acute hemodynamic, hormonal, and pharmacokinetic responses to the oral angiotensin-converting enzyme (ACE) inhibitor spirapril were studied in 15 patients with moderate to severe congestive heart failure in a baseline controlled dose-ranging study.	spirapril	121-130	angiotensin I converting enzyme	Homo sapiens	106-109
1724540-3	1991	All doses demonstrated a significant reduction in serum ACE, even after 24 h. Significant reductions in mean arterial pressure, systemic vascular resistance, and pulmonary capillary wedge pressure were observed with doses greater than 1.0 mg spirapril.	spirapril	242-251	angiotensin I converting enzyme	Homo sapiens	56-59
1764812-8	1991	Compared with the control group, the Spirapril-treated group had significantly lower blood pressure (P less than 0.01), significantly higher PRA (P less than 0.01), a not significantly different plasma AII concentration, and lower plasma and brain ACE activities (P less than 0.01).	spirapril	37-46	angiotensinogen	Rattus norvegicus	202-205
1764812-8	1991	Compared with the control group, the Spirapril-treated group had significantly lower blood pressure (P less than 0.01), significantly higher PRA (P less than 0.01), a not significantly different plasma AII concentration, and lower plasma and brain ACE activities (P less than 0.01).	spirapril	37-46	angiotensin I converting enzyme	Rattus norvegicus	248-251
1764812-9	1991	Interestingly, the brain renin and angiotensinogen mRNA levels of the two groups were similar, but the renal renin mRNA level was significantly higher in the Spirapril-treated group (P less than 0.01).	spirapril	158-167	renin	Rattus norvegicus	109-114
1659958-7	1991	Prolonged daily oral treatment of SHR with spirapril, initiated at the age of 8 weeks and continued for 8 weeks, prevented the development of hypertension with concomitant decrease in aortic ACE activity.	spirapril	43-52	angiotensin I converting enzyme	Rattus norvegicus	191-194
22451874-0	2011	Effect of angiotensin-converting enzyme inhibitor quadropril on dynamic parameters of vascular tone under conditions of NO synthesis blockade in normotensive and spontaneously hypertensive rats.	spirapril	50-60	angiotensin I converting enzyme	Rattus norvegicus	10-39
2561145-1	1989	Spirapril is a new non-sulphydryl angiotensin converting enzyme (ACE) inhibitor which is eliminated mainly through the liver.	spirapril	0-9	angiotensin I converting enzyme	Homo sapiens	65-68
2544729-0	1989	Angiotensin converting enzyme inhibitors: spirapril and related compounds.	spirapril	42-51	angiotensin I converting enzyme	Rattus norvegicus	0-29
2884941-0	1987	Antihypertensive, hemodynamic and autonomic profile of a new angiotensin converting enzyme inhibitor, SCH 33844 (spirapril).	spirapril	102-111	angiotensin I converting enzyme	Rattus norvegicus	61-90
2884941-0	1987	Antihypertensive, hemodynamic and autonomic profile of a new angiotensin converting enzyme inhibitor, SCH 33844 (spirapril).	spirapril	113-122	angiotensin I converting enzyme	Rattus norvegicus	61-90
3036028-0	1987	Angiotensin converting enzyme inhibitory activity of SCH 33844 (spirapril) in rats, dogs and monkeys.	spirapril	53-62	angiotensin I converting enzyme	Rattus norvegicus	0-29
3036028-0	1987	Angiotensin converting enzyme inhibitory activity of SCH 33844 (spirapril) in rats, dogs and monkeys.	spirapril	64-73	angiotensin I converting enzyme	Rattus norvegicus	0-29
3036028-2	1987	SCH 33844 diacid inhibited hydrolysis of the synthetic substrate hippuryl-histidyl-leucine by rabbit lung ACE in vitro with an IC50 (concentration inhibiting enzyme by 50%) of 0.81 nM.	spirapril	0-9	angiotensin-converting enzyme	Oryctolagus cuniculus	106-109
3036028-10	1987	In conclusion, SCH 33844 is a potent, orally effective ACE inhibitor in rats, dogs and monkeys.	spirapril	15-24	angiotensin I converting enzyme	Rattus norvegicus	55-58
2485040-1	1987	Spirapril (SCH 33844; 7-N-[1(S)-ethoxycarbonyl-3-phenylpropyl]-(S)-alanyl-1,4-dithia- 7-azaspiro[4,4]-nonane-8(S)-carboxylic acid) is a new angiotensin-converting enzyme (ACE) inhibitor.	spirapril	0-9	angiotensin I converting enzyme	Rattus norvegicus	140-169
2485040-1	1987	Spirapril (SCH 33844; 7-N-[1(S)-ethoxycarbonyl-3-phenylpropyl]-(S)-alanyl-1,4-dithia- 7-azaspiro[4,4]-nonane-8(S)-carboxylic acid) is a new angiotensin-converting enzyme (ACE) inhibitor.	spirapril	0-9	angiotensin I converting enzyme	Rattus norvegicus	171-174
2485040-2	1987	SCH 33844 diacid inhibited hydrolysis of hip-his-leu by rabbit lung ACE in a potent (Ki = 0.74 nM), selective, and noncompetitive fashion.	spirapril	0-9	angiotensin-converting enzyme	Oryctolagus cuniculus	68-71
29064793-0	2017	[Experience and comparison of antihypertensive effect of ace inhibitor spirapril and calcium antagonist amlodipinein standard and chronotherapeutic prescription mode].	spirapril	71-80	angiotensin I converting enzyme	Homo sapiens	57-60
20930708-5	2011	A series of clinical studies have demonstrated a different effect of the angiotensin-converting enzyme (ACE) inhibitors benazepril, captopril, enalapril, lisinopril, perindopril, quinapril, ramipril, spirapril, and trandolapril when routinely ingested in the morning vs. the evening.	spirapril	200-209	angiotensin I converting enzyme	Homo sapiens	73-102
20930708-5	2011	A series of clinical studies have demonstrated a different effect of the angiotensin-converting enzyme (ACE) inhibitors benazepril, captopril, enalapril, lisinopril, perindopril, quinapril, ramipril, spirapril, and trandolapril when routinely ingested in the morning vs. the evening.	spirapril	200-209	angiotensin I converting enzyme	Homo sapiens	104-107